Menu
← Oncology Approval Tracker
FDA DECISION ·
Fylnetra
pegfilgrastim-pbbk · Kashiv BioSciences
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Pegfilgrastim biosimilar for reduction of infection manifested as febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant risk.
LAMPGEN ANALYSIS
Why it matters
This adds a long-acting growth factor product to an established prevention setting.
What research teams should watch
Track product suffix and confirm timing relative to myelosuppressive treatment.
PRIMARY RECORDS